Potent knockdown of the X RNA of hepatitis B by a novel chimeric siRNA-ribozyme construct and modulation of intracellular target RNA by selectively disabled mutants

Oligonucleotides

Volumn 18, Issue 3, 2008, Pages 225-233

  Gupta, Nidhi ^a   Bano, Aalia S ^a   Sharma, Yogeshwar ^a   Banerjea, Akhil C ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HAMMERHEAD RIBOZYME; RIBOZYME; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ARTICLE; CATALYSIS; CHIMERA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE TARGETING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VIRUS GENE; WILD TYPE; X GENE;

CELL LINE; CLONING, MOLECULAR; HEPATITIS B VIRUS; HUMANS; MUTATION; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING; RNA, VIRAL; TRANS-ACTIVATORS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

MAMMALIA;

EID: 51849108210     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0134     Document Type: Article

References (33)

1. AKKINA, R., BANERJEA, A., BAI, J., ANDERSON, J., Li, M. J., and ROSSI, J.J. (2003). si-RNAs, ribozymes, and RNA decoys in modeling stem cell based gene therapy for HIV/AIDS. Anticancer Res. 23, 1997-1905.
2. ANDERSON, J., BANERJEA, A., and AKKINA, R. (2003). Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4 and CCR5 confer HIV-1 resistance. Oligonucleotides 13, 303-312.
3. ANDERSON, J., and AKKINA, R. (2005). HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bi-specific lentiviral vector. AIDS Res. Ther. 2, 1.
4. BANERJEA, A.C., and JOKLIK, W.K. (1990). Reovirus protein σ1 translated in vitro as well as truncated derivatives of that lack up to two-thirds of its C-terminal portion, exists as two major tetramolecular species that differ in electrophoretic mobility. Virology 179, 460-462.
5. BANERJEA, A., MINGG-JI LI, REMLING, L., ROSSI, J.J., and AKKINA, R. (2004). Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res. Ther. 1, 2.
6. BANERJEA, A.C., CHAKRABORTI, S., UNWALLA, H., GOILA, R., SHRABANI, S., DASH, B.C., SRIRAM, B., PARAMASIVAM, N., and VISWANATHAN, S. (2005). Potential therapeutic applications of DNA-enzymes and siRNAs against viral and cellular genes. In synthetic nucleic acids as inhibitors of gene expression: mechanisms, applications, and therapeutic implications. L. M. Khachigian, ed. (CRC Press, Florida, USA), pp. 115-134.
7. BHINDI, R., FAHMY, R.G., LOWE, H.C., CHESTERMAN, C.N., DASS, C.R., CAIRNS, M.J., SARAVOLAC, E.G., SUN, L-Q., KHACHIGIAN, L.M. (2007). Brother in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid based gene silencing strategies. Am J Path. 171, 1079-1088.
8. CAIRNS, M.J., HOPKINS, T.M., WITHERINGTON, C., WANG, L., and SUN, L.Q. (1999). Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17, 480-486.
9. DONZE, O., and PICARD, D. (2002). RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e45.
10. GOILA, R., and BANERJEA, A.C. (1998). Sequence-specific cleavage of HIV-1 coreceptor-CCR5 gene by a hammerhead ribozyme and a DNA-enzyme: Inhibition of the coreceptor function by DNA-enzyme. FEBS Lett. 436, 233-238.
11. GOILA, R., and BANERJEA, A.C. (2001) Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochemical J. 353, 701-708.
12. GOILA, R., and BANERJEA, A.C. (2004). Sequence specific cleavage of hepatitis X RNA in cis and trans by novel monotarget and multitarget hammerhead motif-containing ribozymes. Oligonucleotides 14, 249-262.
13. GOMEZ-GANZALO, M., CARRETERO, M., RULLAS, J., LARA-PEZZI, E., ARAMBURU, J., BERKHOUT, B., ALCAMI. J., and LOPEZ-CABBERA, M. (2001). The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activating signals. Functional roles of Nf-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol. Chem. 276, 35435-35443.
14. GUPTA, N., SOOD, V., BANO, A.S., and BANERJEA, A.C. (2007). X protein of hepatitis B virus potently activates HIV-1 subtype C-LTR promoter: implications for faster spread of HIV-1 subtype-C. AIDS 21, 1491-1492.
15. GUPTA, N., BANO, A.S., SHARMA, Y., SOOD, V., and BANERJEA, A.C. (2008). Potent intracellular knock down of Hepatitis B virus X RNA by catalytic hammerhead ribozymes or DNA-enzymes with antisense DNA-oligonucleotides or 10-23 DNA-enzymes that powerfully augment in vitro sequence-specific cleavage activities. The Open Biotechnology Journal, 2, 1-12. (Open Access) The URL to access to the article http://www.bentham.org/open/tobiotj/openaccess2.htm
16. JOYCE, G.F. (2004). Directed evolution of nucleic acid enzymes. Ann. Rev. Biochem. 73, 791-736.
17. KUMAR, V., JAYASURYAN, N., and KUMAR, R. (1996). A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci USA 93, 5647-5652.
18. KURRECK, J., BIEBER, B., JAHNEL, R., and ERDMANN, V.A. (2002). Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype 1. J. Biol. Chem. 277, 7099-8007.
19. KURRECK, J. (2003). Antisense technologies: Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
20. LEIRDAL, M., and SIOUD, M. (2002). Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem. Biophys. Res. Comm. 295, 744-748.
21. MARTIM, S.E., and CAPLEIN, N.J. (2007). Applications of RNA interference in mammalian systems. Annu. Rev. Genomics Hum. Genet. 8, 81-108.
22. MARTINEZ, M.A., GUTIERREZ, A., ARMAND-UGON, M., BLANCO, J., PARERA, M., GOMEZ, J., CLOTET, B., and ESTE. J.A. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16, 2385-2390.
23. PAIK, S., BANERJEA, A., HARMISON, G.G., CHEN, C.J., and SCHUBERT, M. (1997). Defective HIV-1 provirus encoding a multitarget ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny and protects the cells from pathogenesis. Human Gene Ther. 8, 1115-1124.
24. RAMEZANI, A., MA, X.Z., AMELI, M., ARORA, A., and JOSHI, S. (2006). Assessment of an anti-HIV-1 combination gene therapy strategy using antisense RNA and multimeric hammerhead ribozymes. Front. Biosci. 11, 2940-2948.
25. ROBINSON, W.S. (1994). Molecular events in pathogenesis of hepadnaviruses associated hepatocellular carcinoma. Annu. Rev. Med. 45, 297-223.
26. ROSSI, J.J. (2006). RNAi as a treatment for HIV-1 infection. Biotechniques Suppl: 25-29.
27. SCHERER, L., and ROSSI, J. J. (2004). RNAi applications in mammalian cells. Biotechniques 36, 557-561.
28. SCHUBERT, S., FURSTE, J.P., WERK, D., GRUNERT, H.P., ZEICHHARDT, H., ERDMANN, V.A., and KURRECK, J. (2004). Gaining target access for deoxyribozymes. J. Mol. Biol. 339, 355-363.
29. SCHUBERT, S., and KURRECK, J. (2006). Oligonucleotide-based antiviral strategies. Handb. Exp. Pharmacol. 173, 261-287.
30. SHAHI, S., SHANMUGASUNDARAM, G.K., and BANERJEA, A.C. (2001). Ribozymes that cleave reovirus genome segments S1 also protect cells from pathogenesis caused by reovirus infection. Proc. Nat. Acad. Sci. USA 98, 4101-4106.
31. SOOD, V., GUPTA, N., BANO, A.S., and BANERJEA, A.C. (2007). DNA-enzyme mediated cleavage of human immunodeficiency virus type 1 Gag RNA is significantly augmented by antisense-DNA molecules targeted to hybridize close to the cleavage site. Oligonucleotides 17, 113-121.
32. UNWALLA, H. CHAKRABORTI, S., SOOD, V., GUPTA, N., and BANERJEA, A.C. (2006). Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme. Antiviral Res. 72, 134-144.
33. ZHOU, J, LI, H., ZAIA J., and ROSSI, J.J. (2008). Novel dual inhibitory function apatamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. May 6 [Epub ahead of print].